Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan

AI Briefing

• – Ono submits application for ripretinib approval in Japan for advanced gastrointestinal stromal tumor
• – Ripretinib developed by Deciphera Pharmaceuticals, based on results of INVICTUS study
• – Global Phase 3 clinical trial results indicate efficacy of ripretinib in treating cancer chemotherapy-resistant gastrointestinal stromal tumor